The PIONEER REAL Switzerland study evaluated the real-world effectiveness and safety of oral semaglutide in adults with type 2 diabetes (T2D) in Switzerland. The study involved 185 participants who were treatment-naive to injectable glucose-lowering medications and initiated oral semaglutide in routine clinical practice. The primary endpoint was the change in HbA1c from baseline to end of study (EOS), with secondary endpoints including changes in body weight and the proportion of participants achieving HbA1c < 7.0%. The study found significant reductions in HbA1c (-0.91%) and body weight (-4.85%) compared to baseline. At EOS, 64.2% of participants had HbA1c < 7.0%, and 37.8% achieved a composite endpoint of HbA1c reduction ≥1% and body weight reduction ≥3% or ≥5%. Most adverse events were mild or moderate, with gastrointestinal disorders being the most common. Six serious adverse events were reported, none of which were considered related to oral semaglutide. The study concluded that oral semaglutide achieved clinically significant improvements in HbA1c and body weight in adults with T2D in Switzerland, with no new safety signals. The findings support the use of oral semaglutide in real-world settings, similar to results from clinical trials. The study highlights the effectiveness of oral semaglutide in improving glycaemic control and weight loss in T2D patients, with a safety profile consistent with previous trials. The results suggest that oral semaglutide is a viable treatment option for adults with T2D in routine clinical practice.The PIONEER REAL Switzerland study evaluated the real-world effectiveness and safety of oral semaglutide in adults with type 2 diabetes (T2D) in Switzerland. The study involved 185 participants who were treatment-naive to injectable glucose-lowering medications and initiated oral semaglutide in routine clinical practice. The primary endpoint was the change in HbA1c from baseline to end of study (EOS), with secondary endpoints including changes in body weight and the proportion of participants achieving HbA1c < 7.0%. The study found significant reductions in HbA1c (-0.91%) and body weight (-4.85%) compared to baseline. At EOS, 64.2% of participants had HbA1c < 7.0%, and 37.8% achieved a composite endpoint of HbA1c reduction ≥1% and body weight reduction ≥3% or ≥5%. Most adverse events were mild or moderate, with gastrointestinal disorders being the most common. Six serious adverse events were reported, none of which were considered related to oral semaglutide. The study concluded that oral semaglutide achieved clinically significant improvements in HbA1c and body weight in adults with T2D in Switzerland, with no new safety signals. The findings support the use of oral semaglutide in real-world settings, similar to results from clinical trials. The study highlights the effectiveness of oral semaglutide in improving glycaemic control and weight loss in T2D patients, with a safety profile consistent with previous trials. The results suggest that oral semaglutide is a viable treatment option for adults with T2D in routine clinical practice.